+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
Age: 18Years +
All Genders
ID06384807

Dose Escalation and Expansion Study of BHV-1510 Alone and With Cemiplimab in Advanced Solid Tumors

Led by Biohaven Therapeutics Ltd. · Updated on 2026-09-28

500

Participants Needed

17

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a Phase 12, first-in-human, open-label study of BHV-1510, an antibody-drug conjugate targeting Trop-2, in participants with advanced solid tumors that have been previously treated. The study aims to evaluate the safety, tolerability, and preliminary effectiveness of BHV-1510 alone and in combination with cemiplimab, an anti-cancer agent, in patients with tumors resistant to standard therapies. This trial is multicenter and sponsored by Biohaven Therapeutics Ltd. The study has two parts Phase 1 includes dose escalation to determine safe and tolerable doses of BHV-1510 as monotherapy and combined with cemiplimab, identifying recommended doses for expansion and maximum tolerated doses. Phase 2 expands to evaluate preliminary effectiveness in different tumor cohorts using the established doses. BHV-1510 is administered intravenously in different schedules every 2 or 3 weeks, sometimes with doses on Day 1 and Day 8, and cemiplimab is given as a 350mg IV infusion every 3 weeks, alone or in combination. Participants will undergo regular assessments including monitoring adverse events throughout the study, pharmacokinetic blood sampling at specific time points, and tumor response evaluations using established criteria. The study tracks objective response rates, duration of response, and survival outcomes over an average of 47 months. Safety, drug levels, and immune responses are closely monitored. The total trial duration may extend up to approximately 47 months, ensuring comprehensive evaluation and follow-up of participant outcomes.

CONDITIONS

Brief Title

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Research Team

C

Chief Medical Officer

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here